Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 1,236 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,236 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $21.52, for a total transaction of $26,598.72. Following the sale, the insider now directly owns 74,627 shares of the company's stock, valued at $1,605,973.04. This represents a 1.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Castle Biosciences Trading Down 3.2 %

CSTL opened at $21.27 on Thursday. The company has a fifty day moving average price of $21.29 and a two-hundred day moving average price of $26.71. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84. The company has a market cap of $613.53 million, a P/E ratio of 106.36 and a beta of 1.11. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02.

Institutional Trading of Castle Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CSTL. Covestor Ltd bought a new position in Castle Biosciences in the fourth quarter worth approximately $25,000. R Squared Ltd bought a new stake in shares of Castle Biosciences during the fourth quarter valued at approximately $42,000. GAMMA Investing LLC raised its position in shares of Castle Biosciences by 1,865.8% during the first quarter. GAMMA Investing LLC now owns 4,364 shares of the company's stock worth $87,000 after purchasing an additional 4,142 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Castle Biosciences in the 4th quarter worth $128,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock valued at $158,000 after purchasing an additional 604 shares during the period. 92.60% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades




Several research firms have recently weighed in on CSTL. Guggenheim set a $30.00 price objective on shares of Castle Biosciences and gave the stock a "buy" rating in a research report on Friday, March 28th. Robert W. Baird increased their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Finally, Stephens reissued an "overweight" rating and issued a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $38.75.

View Our Latest Research Report on Castle Biosciences

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.

Recommended Stories

Insider Buying and Selling by Quarter for Castle Biosciences (NASDAQ:CSTL)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.

Insider Buying or Selling at Castle Biosciences?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Castle Biosciences and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles